[News] ESMO Congress 2025

Sara A Hurvitz (Fred Hutch Cancer Center, Seattle, WA, USA) and colleagues presented results from the randomised, open-label, phase 3, VIKTORIA-1 trial in 392 patients with HR+/HER2- advanced breast cancer. Medium progression-free survival was 9·3 months in patients receiving the triplet combination of gedatolisib (180 mg, intravenous, once weekly for 3 weeks), fulvestrant (500 mg, intramuscular, every 2 weeks [cycle 1] then every 4 weeks) and palbociclib (125 mg, once daily for 21 days) compared with 2·0 months (hazard ratio [HR] 0·24; 95% CI 0·17–0·35; p<0·0001) for patients receiving fulvestrant alone and 7·4 months (HR 0·33; 0·24–0·48; p<0·0001) for those receiving the doublet combination of gedatolisib plus fulvestrant.